Inclusion Criteria:~* Subject has the ability to understand the requirements of the study, provide written
informed consent, and abide by the requirements of the study. In addition, a member of the subject's family or
a legally authorized representative must consent to the subject's participation in the study.~* Subject has a
caregiver willing to assist the subject's involvement in the study.~* Subject is a male or female between the
ages of 50 and 80 with a body mass index (BMI) below 31. Females must be post-menopausal at least 1 year or
surgically sterilized.~* Subject must have a cognitive deficit present for at least 1 year and meet DSM -IV
criteria for Alzheimer's disease and meet National Institute of Neurological and Communicative Disorders and
Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria for the presence of
probable Alzheimer's disease.~* Subject's severity of Alzheimer's disease must be mild-moderate, documented
with a Mini Mental State Exam (MMSE) score of 12-26.~* Subject has a computerized tomography (CT) scan or
magnetic resonance imaging (MRI) within the prior 12 months which is compatible with a diagnosis of probable
AD.~* If a subject is being treated for Alzheimer's disease, it must be with a single cholinesterase inhibitor
(donepezil, rivastigmine, or galantamine), with or without memantine, and with a dose which has been stable for
at least 3 months prior to dosing.~* Subject performance status is ≤ 3 on items 1 through 5 and ≤ 2 on item 6
from the Degree of Disability Section of the Rapid Disability Scale-2~* Subject agrees not to donate blood or
blood products while participating in this study and for at least 60 days after discontinuing from the study.~
